1. Home
  2. VYGR vs SLN Comparison

VYGR vs SLN Comparison

Compare VYGR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • SLN
  • Stock Information
  • Founded
  • VYGR 2013
  • SLN 1994
  • Country
  • VYGR United States
  • SLN United Kingdom
  • Employees
  • VYGR N/A
  • SLN N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VYGR Health Care
  • SLN Health Care
  • Exchange
  • VYGR Nasdaq
  • SLN Nasdaq
  • Market Cap
  • VYGR 342.5M
  • SLN 352.2M
  • IPO Year
  • VYGR 2015
  • SLN N/A
  • Fundamental
  • Price
  • VYGR $5.22
  • SLN $5.56
  • Analyst Decision
  • VYGR Strong Buy
  • SLN Strong Buy
  • Analyst Count
  • VYGR 9
  • SLN 4
  • Target Price
  • VYGR $15.53
  • SLN $61.50
  • AVG Volume (30 Days)
  • VYGR 361.6K
  • SLN 439.4K
  • Earning Date
  • VYGR 02-26-2025
  • SLN 03-11-2025
  • Dividend Yield
  • VYGR N/A
  • SLN N/A
  • EPS Growth
  • VYGR N/A
  • SLN N/A
  • EPS
  • VYGR 0.47
  • SLN N/A
  • Revenue
  • VYGR $163,784,000.00
  • SLN $21,773,221.00
  • Revenue This Year
  • VYGR N/A
  • SLN N/A
  • Revenue Next Year
  • VYGR N/A
  • SLN $104.98
  • P/E Ratio
  • VYGR $11.19
  • SLN N/A
  • Revenue Growth
  • VYGR 3.40
  • SLN N/A
  • 52 Week Low
  • VYGR $4.99
  • SLN $4.82
  • 52 Week High
  • VYGR $10.66
  • SLN $27.72
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 38.79
  • SLN 33.35
  • Support Level
  • VYGR $4.99
  • SLN $4.82
  • Resistance Level
  • VYGR $5.45
  • SLN $7.87
  • Average True Range (ATR)
  • VYGR 0.26
  • SLN 0.65
  • MACD
  • VYGR -0.05
  • SLN 0.02
  • Stochastic Oscillator
  • VYGR 17.97
  • SLN 22.70

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Share on Social Networks: